Cable Hill Partners’s Audentes Therapeutics, Inc BOLD Stock Holding History

Cable Hill Partners’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10	Closed	–	–	815
2019 Q1	$0	Buy	+10	New	+$287	﹤0.01%	856

Other funds holding BOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cable Hill Partners's BOLD Position: Q2 2019 in Review

Cable Hill Partners sold out of Audentes Therapeutics, Inc (BOLD) in Q2 2019, closing a stake of 10 shares.

Cable Hill Partners first reported a position in BOLD in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 147 funds tracked by Wall St. Rank hold BOLD as of Q2 2019.

Cable Hill Partners reported no remaining Audentes Therapeutics, Inc position as of Q2 2019 after selling out during the quarter.
Cable Hill Partners sold 10 Audentes Therapeutics, Inc shares in Q2 2019.
Cable Hill Partners first reported a position in Audentes Therapeutics, Inc in Q1 2019 and held it in 1 quarter.
Cable Hill Partners's Audentes Therapeutics, Inc position peaked at $0 in Q1 2019.
147 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.